ClinicalTrials.gg
CompletedNCT00569270Updated Aug 20, 2019Results posted

Dynamic Hyperinflation and Tiotropium

A Phase 4 interventional study of Placebo in COPD, sponsored by Gelb, Arthur F., M.D.. Completed at 2 sites in 2 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-08-20.

Sponsored by Gelb, Arthur F., M.D. · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States — 139 open to participants now, 174 under way, 21 of them phase 3. Pulmonary Disease, Chronic Obstructive · United States.

Enrollment
750th of 1,039
30 · median 100
Started
2006
with 42 others
Phase 4
98 of 1,280
6 open now
Registered
151st of 1,280
by date

Among the 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, this one is the 750th largest by enrollment of the 1,039 interventional ones that give a count, is one of 43 that started in 2006, is one of 98 in phase 4, and was the 151st registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

139 of the 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States are open now. Recruiting first, the newest first:

134 more — sign in →

All 139 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, or all of them as a file.
02

Study summary

We will detect dynamic hyperinflation (DH) in 40 COPD (chronic obstructive pulmonary disease) patients with moderately severe disease using metronome paced hyperventilation (MPH) with inspiratory capacity as the primary end point. Hypothesis: Is tiotropium capable of lung volume protecting inspiratory capacity from MPH induced DH vs placebo in a randomized crossover double blinded study.

Read the detailed description

Study completed with 29 patients studied. Data is being analyzed to evaluate trough and peak effect of 18 µg tiotropium vs placebo on FEV 1 (L)(forced expiratory capacity in one second), inspiratory capacity and functional residual volume. In addition, we will study the effect of 18 µg tiotropium vs placebo on metronome paced hyperventilation induced dynamic hyperinflation. We will also evaluate the effect of tiotropium induced increase in IC (inspiratory capacity) vs extent of emphysema as evaluated on high resolution thin section CT lung

03

Conditions studied

04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderately severe patients age 40-85 yr with post 180ug albuterol FEV 1 between 60 and 79% predicted and FEV 1/FVC \< 70%.
  • Smoking history > 10 pack yr.
  • Clinically stable X 6 weeks.
  • No oxygen usage.

Exclusion criteria

Exclusion Criteria:

  • History of asthma
  • Clinically unstable
  • Any other significant medical problem precluding full cooperation for study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    Tiotropium 18 µg capsule, bronchodilator

    tiotropium 18 µg capsule for 1 month versus placebo. To study bronchodilation and effect following metronome paced hyperventilation and induced dynamic hyperinflation of active tiotropium versus placebo

    Drug: Placebo

  • Placebo comparator
    2

    placebo 18ug tiotropium for 1 month

    Drug: Placebo

Interventions

  • DrugPlacebo

    Procedure/Surgery - tiotropium 18ug capsule daily for 1 month vs placebo to study the effect of trough and peak effect on bronchodilation and effect of metronome paced hyperventilation induced dynamic hyperinflation

06

What researchers measure

Primary outcomes

  1. Bronchodilator Response:Peak FEV1(L)(Forced Expiratory Volume in One Second)-

    Lung function studies (mean +/- SD): peak FEV1 (+2h) after 30 days of placebo or tiotropium in 29 moderate COPD patients. FEV1 = Forced expiratory volume in one second

    Time frame: 30 days

  2. Bronchodilator Response:Peak FRC (L) (Functional Residual Capacity)

    Lung function studies (mean +/- SD): peak FRC after 30 days (+2h) of placebo or tiotropium in 29 moderate COPD patients.

    Time frame: 30 days

  3. Bronchodilator Response: Peak FVC (L) (Forced Vital Capacity)- Tiotropium and Placebo

    Lung function studies (mean +/- SD) of peak forced vital capaciy (L) after 30 days (+2h) of tiotropium versus placebo in 29 moderate COPD patients. Forced vital capacity - liters

    Time frame: 30 days

  4. Bronchodilator Response: Peak IC (L) - (Inspiratory Capacity) - Tiotropium Versus Placebo

    Lung function studies (mean +/- SD) - Peak inspiratory capacity after 30 days (+2h)of tiotropium versus placebo in 29 moderate COPD patients. Inspiratory capacity- liters

    Time frame: 30 days

  5. Bronchodilator Response: Peak FRC/TLC Percentage (Functional Residual Capacity(L)/Total Lung Capacity(L) - Tiotropium or Placebo

    Lung function studies (mean +/- SD) peak Peak FRC/TLC after 30 days (+2h)of tiotropium versus placebo in 29 moderate COPD patients. Functional residual capacity/total lung capacity - percentage

    Time frame: 30 days

  6. Bronchodilator Response: Peak TLC (L) (Total Lung Capacity)- Tiotropium or Placebo

    Net change in lung function studies (mean +/- SE) from baseline to trough (-1h) and peak (+2h) after 30 days of tiotropium versus placebo in 29 moderate COPD patients. Total lung capacity - liters

    Time frame: 30 days

  7. Bronchodilator Response: Trough FEV1 (L)- (Forced Expiratory Volume) Tiotropium Versus Placebo

    Lung function studies Trough FEV1(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients. Forced expiratory volume in 1s (liters)

    Time frame: 30 days

  8. Bronchodilator Response: Trough FRC (L)- Tiotropium Versus Placebo

    Lung function studies Trough FRC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients. Functional residual capacity(liters)

    Time frame: 30 days

  9. Bronchodilator Response: Trough FVC (L)- (Forced Vital Capacity) Tiotropium Versus Placebo

    Lung function studies Trough FVC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients

    Time frame: 30 days

  10. Bronchodilator Response: Trough IC (L) Inspiratory Capacity - Tiotropium Versus Placebo

    Lung function studies (Trough IC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients Trough inspiratory capacity- liters

    Time frame: 30 days

  11. Bronchodilator Response: Trough FRC/TLC (Functional Residual Capacity/Total Lung Capacity)- Tiotropium Versus Placebo

    Lung function studies Trough FRC/TLC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients Trough Functional residual capacity/total lung capacity - percentage

    Time frame: 30 days

  12. Bronchodilator Response: Trough TLC (L) (Total Lung Capacity)- Tiotropium Versus Placebo

    Lung function studies Trough TLC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients

    Time frame: 30 days

  13. IC (Inspiratory Capacity L)and Metronome Paced Hyperventilation-induced Dynamic Hyperinflation in Tiotropium Cohort Versus Placebo and Baseline

    IC measurement before and after metronome paced hyperventilation-induced dynamic hyperinflation at baseline and in tiotropium and placebo groups. Measure ratio of functional residual capacity divided by total lung capacity at baseline and after 30 days of tiotropium versus placebo

    Time frame: baseline and 30 days (+2h) post dose

  14. TLC (L) Before and After Metronome Paced Hyperventilation Induced Dynamic Hyperinflation in Tiotropium Cohort Versus Placebo

    Total lung capacity before and after metronome paced hyperventilation induced dynamic hyperinflation in tiotropium cohort versus placebo. Difference between TLC measured at one hour before intervention \& 2 hrs. after after 30 days of treatment with either placebo or tiotropium

    Time frame: one hour before intervention & 2 hrs. after after 30 days

Secondary outcomes

  1. Extent of Lung CT Scored Emphysema and and Lung Function of FEV1(l) After Tiotropium

    Correlation between improved lung function after tiotropium and extent of lung CT scored emphysema with respect to FEV 1; correlation of tiotropium induced bronchodilation and extent of lung ct scored emphysema; measures include increase in FEV1 from baseline to peak tiotropium

    Time frame: baseline to 30 days

  2. IC (Inspiratory Capacity, L) Post Mph (Metronome Paced Hyperventilation) Induced dh (Dynamic Hyperinflation) After Tiotropium and Extent of Lung CT Scored Emphysema

    Correlation between change in inspiratory capacity (L) post metronome paced hyperventilation induced dynamic hyperinflation and extent of lung ct scored emphysema

    Time frame: baseline to 30 days

  3. Extent of Lung CT Scored Emphysema and and Lung Function of FRC/TLC (Functional Residual Capacity(L)/Total Lung Capacity (L) After Tiotropium

    Correlation between improved lung function after tiotropium and extent of lung CT scored emphysema with respect to ratio functional residual capacity divided by total lung capacity. Specifically, correlation of tiotropium induced bronchodilation and extent of lung ct scored emphysema

    Time frame: baseline to trough tiotropium

07

Results

Posted Oct 5, 2012

Participant flow

Patients with COPD (chronic obstructive pulmonary disease), GOLD (Global Initiative for Chronic Obstructive Lung Disease)Stage 2 were recruited from pulmonary out-patient offices at Mt. Sinai Hosp. Toronto and from Arthur F Gelb MD Lakewood, Calif from June 2009 thru January 2010

Period: First Intervention
Participant flow — Period: First Intervention
MilestoneTiotropium 18 µg Capsule First, Then PlaceboPlacebo First, Then Tiotropium Bromide 18 µg
Started1515
Completed1514
Not completed01
Withdrew: Protocol violation01
Period: Second Intervention
Participant flow — Period: Second Intervention
MilestoneTiotropium 18 µg Capsule First, Then PlaceboPlacebo First, Then Tiotropium Bromide 18 µg
Started1514
29 days1514
Completed1514
Not completed00

Outcome measures

PrimaryBronchodilator Response:Peak FEV1(L)(Forced Expiratory Volume in One Second)-

Lung function studies (mean +/- SD): peak FEV1 (+2h) after 30 days of placebo or tiotropium in 29 moderate COPD patients. FEV1 = Forced expiratory volume in one second

Time frame:
30 days
Reported as:
Mean · liters
Bronchodilator Response:Peak FEV1(L)(Forced Expiratory Volume in One Second)-
litersPlaceboTiotropium
Bronchodilator Response:Peak FEV1(L)(Forced Expiratory Volume in One Second)-1.74 ± 0.581.82 ± 0.59
Statistical analysis
  • Placebo vs Tiotropium · Mixed Models Analysis · p = 0.027 (a priori threshold for statistical significance: p\<0.05)
SecondaryExtent of Lung CT Scored Emphysema and and Lung Function of FEV1(l) After Tiotropium

Correlation between improved lung function after tiotropium and extent of lung CT scored emphysema with respect to FEV 1; correlation of tiotropium induced bronchodilation and extent of lung ct scored emphysema; measures include increase in FEV1 from baseline to peak tiotropium

Time frame:
baseline to 30 days
Reported as:
Mean · percentage of lung tissue
Extent of Lung CT Scored Emphysema and and Lung Function of FEV1(l) After Tiotropium
percentage of lung tissueLung CT Scored Emphysema and FEV1
Extent of Lung CT Scored Emphysema and and Lung Function of FEV1(l) After Tiotropium13.68 ± 18.84
Statistical analysis
  • Lung CT Scored Emphysema and FEV1 · Spearman rho · p = 0.96 (A priori threshold for statistical significance: p=0.05) · Spearman rho: 0.19
PrimaryBronchodilator Response:Peak FRC (L) (Functional Residual Capacity)

Lung function studies (mean +/- SD): peak FRC after 30 days (+2h) of placebo or tiotropium in 29 moderate COPD patients.

Time frame:
30 days
Reported as:
Mean · Liters
Bronchodilator Response:Peak FRC (L) (Functional Residual Capacity)
LitersPlaceboTiotropium
Bronchodilator Response:Peak FRC (L) (Functional Residual Capacity)3.80 ± 0.793.72 ± 0.84
Statistical analysis
  • Placebo vs Tiotropium · Mixed Models Analysis · p = 0.318 (A priori threshold for statistical significance: p\<0.05)
PrimaryBronchodilator Response: Peak FVC (L) (Forced Vital Capacity)- Tiotropium and Placebo

Lung function studies (mean +/- SD) of peak forced vital capaciy (L) after 30 days (+2h) of tiotropium versus placebo in 29 moderate COPD patients. Forced vital capacity - liters

Time frame:
30 days
Reported as:
Mean · liters
Bronchodilator Response: Peak FVC (L) (Forced Vital Capacity)- Tiotropium and Placebo
litersPlaceboTiotropium 18 µg Capsule, Bronchodilator
Bronchodilator Response: Peak FVC (L) (Forced Vital Capacity)- Tiotropium and Placebo3.17 ± 1.133.27 ± 1.16
Statistical analysis
  • Placebo · Mixed Models Analysis · p = 0.078 (Statistical significance was p \< 0.05)
SecondaryIC (Inspiratory Capacity, L) Post Mph (Metronome Paced Hyperventilation) Induced dh (Dynamic Hyperinflation) After Tiotropium and Extent of Lung CT Scored Emphysema

Correlation between change in inspiratory capacity (L) post metronome paced hyperventilation induced dynamic hyperinflation and extent of lung ct scored emphysema

Time frame:
baseline to 30 days
Reported as:
Mean · percentage of lung tissue
IC (Inspiratory Capacity, L) Post Mph (Metronome Paced Hyperventilation) Induced dh (Dynamic Hyperinflation) After Tiotropium and Extent of Lung CT Scored Emphysema
percentage of lung tissueLung CT Scored Emphysema and IC
IC (Inspiratory Capacity, L) Post Mph (Metronome Paced Hyperventilation) Induced dh (Dynamic Hyperinflation) After Tiotropium and Extent of Lung CT Scored Emphysema13.68 ± 18.84
Statistical analysis
  • Lung CT Scored Emphysema and IC · Spearman rho · p = 0.4 · Spearman rho: -0.26
PrimaryBronchodilator Response: Peak IC (L) - (Inspiratory Capacity) - Tiotropium Versus Placebo

Lung function studies (mean +/- SD) - Peak inspiratory capacity after 30 days (+2h)of tiotropium versus placebo in 29 moderate COPD patients. Inspiratory capacity- liters

Time frame:
30 days
Reported as:
Mean · liters
Bronchodilator Response: Peak IC (L) - (Inspiratory Capacity) - Tiotropium Versus Placebo
litersPlaceboTiotropium
Bronchodilator Response: Peak IC (L) - (Inspiratory Capacity) - Tiotropium Versus Placebo2.12 ± 0.822.24 ± 0.80
Statistical analysis
  • Placebo vs Tiotropium · Mixed Models Analysis · p = 0.067 (A priori threshold for statistical significance: p\<0.05)
PrimaryBronchodilator Response: Peak FRC/TLC Percentage (Functional Residual Capacity(L)/Total Lung Capacity(L) - Tiotropium or Placebo

Lung function studies (mean +/- SD) peak Peak FRC/TLC after 30 days (+2h)of tiotropium versus placebo in 29 moderate COPD patients. Functional residual capacity/total lung capacity - percentage

Time frame:
30 days
Reported as:
Mean · percentage of FRC/TLC
Bronchodilator Response: Peak FRC/TLC Percentage (Functional Residual Capacity(L)/Total Lung Capacity(L) - Tiotropium or Placebo
percentage of FRC/TLCPlaceboTiotropium
Bronchodilator Response: Peak FRC/TLC Percentage (Functional Residual Capacity(L)/Total Lung Capacity(L) - Tiotropium or Placebo0.65 ± 0.100.66 ± 0.17
Statistical analysis
  • Placebo vs Tiotropium · Regression, Logistic · p = 0.615 (A priori threshold for statistical significance: p\<0.05)
PrimaryBronchodilator Response: Peak TLC (L) (Total Lung Capacity)- Tiotropium or Placebo

Net change in lung function studies (mean +/- SE) from baseline to trough (-1h) and peak (+2h) after 30 days of tiotropium versus placebo in 29 moderate COPD patients. Total lung capacity - liters

Time frame:
30 days
Reported as:
Mean · liters
Bronchodilator Response: Peak TLC (L) (Total Lung Capacity)- Tiotropium or Placebo
litersPlaceboTiotropium
Bronchodilator Response: Peak TLC (L) (Total Lung Capacity)- Tiotropium or Placebo5.91 ± 1.225.82 ± 1.35
Statistical analysis
  • Placebo · Mixed Models Analysis · p = 0.325 (Statistical significance was p\<0.05)
PrimaryBronchodilator Response: Trough FEV1 (L)- (Forced Expiratory Volume) Tiotropium Versus Placebo

Lung function studies Trough FEV1(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients. Forced expiratory volume in 1s (liters)

Time frame:
30 days
Reported as:
Mean · liters
Bronchodilator Response: Trough FEV1 (L)- (Forced Expiratory Volume) Tiotropium Versus Placebo
litersPlaceboTiotropium
Bronchodilator Response: Trough FEV1 (L)- (Forced Expiratory Volume) Tiotropium Versus Placebo1.68 ± 0.541.71 ± 0.56
Statistical analysis
  • Placebo · Mixed Models Analysis · p = 0.345
PrimaryBronchodilator Response: Trough FRC (L)- Tiotropium Versus Placebo

Lung function studies Trough FRC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients. Functional residual capacity(liters)

Time frame:
30 days
Reported as:
Mean · liters
Bronchodilator Response: Trough FRC (L)- Tiotropium Versus Placebo
litersPlaceboTiotropium
Bronchodilator Response: Trough FRC (L)- Tiotropium Versus Placebo3.84 ± 0.843.66 ± 0.88
Statistical analysis
  • Placebo vs Tiotropium · Mixed Models Analysis · p = 0.068 (A priori threshold for statistical significance: p\<0.05)
PrimaryBronchodilator Response: Trough FVC (L)- (Forced Vital Capacity) Tiotropium Versus Placebo

Lung function studies Trough FVC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients

Time frame:
30 days
Reported as:
Mean · liters
Bronchodilator Response: Trough FVC (L)- (Forced Vital Capacity) Tiotropium Versus Placebo
litersPlaceboTiotropium
Bronchodilator Response: Trough FVC (L)- (Forced Vital Capacity) Tiotropium Versus Placebo3.12 ± 1.103.15 ± 1.13
Statistical analysis
  • Placebo vs Tiotropium · Mixed Models Analysis · p = 0.589 (A priori threshold for statistical significance: p\<0.05)
PrimaryBronchodilator Response: Trough IC (L) Inspiratory Capacity - Tiotropium Versus Placebo

Lung function studies (Trough IC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients Trough inspiratory capacity- liters

Time frame:
30 days
Reported as:
Mean · liters
Bronchodilator Response: Trough IC (L) Inspiratory Capacity - Tiotropium Versus Placebo
litersPlaceboTiotropium
Bronchodilator Response: Trough IC (L) Inspiratory Capacity - Tiotropium Versus Placebo2.17 ± 0.772.11 ± 0.83
Statistical analysis
  • Placebo vs Tiotropium · Mixed Models Analysis · p = 0.922 (A priori threshold for statistical significance: p\<0.05)
PrimaryBronchodilator Response: Trough FRC/TLC (Functional Residual Capacity/Total Lung Capacity)- Tiotropium Versus Placebo

Lung function studies Trough FRC/TLC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients Trough Functional residual capacity/total lung capacity - percentage

Time frame:
30 days
Reported as:
Mean · percentage of FRC/TLC
Bronchodilator Response: Trough FRC/TLC (Functional Residual Capacity/Total Lung Capacity)- Tiotropium Versus Placebo
percentage of FRC/TLCPlaceboTiotropium
Bronchodilator Response: Trough FRC/TLC (Functional Residual Capacity/Total Lung Capacity)- Tiotropium Versus Placebo0.64 ± 0.090.62 ± 0.09
Statistical analysis
  • Placebo vs Tiotropium · Mixed Models Analysis · p = -0.02 (A priori threshold for statistical significance: p\<0.05)
PrimaryBronchodilator Response: Trough TLC (L) (Total Lung Capacity)- Tiotropium Versus Placebo

Lung function studies Trough TLC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients

Time frame:
30 days
Reported as:
Mean · liters
Bronchodilator Response: Trough TLC (L) (Total Lung Capacity)- Tiotropium Versus Placebo
litersPlaceboTiotropium
Bronchodilator Response: Trough TLC (L) (Total Lung Capacity)- Tiotropium Versus Placebo5.99 ± 1.185.86 ± 1.25
Statistical analysis
  • Placebo vs Tiotropium · Mixed Models Analysis · p = -0.13 (A priori threshold for statistical significance: p\<0.05)
PrimaryIC (Inspiratory Capacity L)and Metronome Paced Hyperventilation-induced Dynamic Hyperinflation in Tiotropium Cohort Versus Placebo and Baseline

IC measurement before and after metronome paced hyperventilation-induced dynamic hyperinflation at baseline and in tiotropium and placebo groups. Measure ratio of functional residual capacity divided by total lung capacity at baseline and after 30 days of tiotropium versus placebo

Time frame:
baseline and 30 days (+2h) post dose
Reported as:
Mean · liters
IC (Inspiratory Capacity L)and Metronome Paced Hyperventilation-induced Dynamic Hyperinflation in Tiotropium Cohort Versus Placebo and Baseline
litersBefore DH (Dynamic Hyperinflation)After DH (Dynamic Hyperinflation
Baseline IC (inspiratory capacity)2.09 ± 0.831.76 ± 0.70
Placebo IC2.17 ± 0.821.80 ± 0.70
Tiotropium IC2.24 ± 0.801.80 ± 0.74
Statistical analysis
  • Before DH (Dynamic Hyperinflation) vs After DH (Dynamic Hyperinflation · Mixed Models Analysis · p = 0.0001 (A priori threshold for statistical significance: p\<0.05)
PrimaryTLC (L) Before and After Metronome Paced Hyperventilation Induced Dynamic Hyperinflation in Tiotropium Cohort Versus Placebo

Total lung capacity before and after metronome paced hyperventilation induced dynamic hyperinflation in tiotropium cohort versus placebo. Difference between TLC measured at one hour before intervention \& 2 hrs. after after 30 days of treatment with either placebo or tiotropium

Time frame:
one hour before intervention & 2 hrs. after after 30 days
Reported as:
Mean · liters
TLC (L) Before and After Metronome Paced Hyperventilation Induced Dynamic Hyperinflation in Tiotropium Cohort Versus Placebo
liters2h Post Placebo TLC(L)TLC (L) 2h Post Tiotropium
Before DH (dynamic hyperinflation)5.96 ± 1.225.84 ± 1.35
After DH5.84 ± 1.135.78 ± 1.14
Statistical analysis
  • 2h Post Placebo TLC(L) vs TLC (L) 2h Post Tiotropium · Mixed Models Analysis · p = >0.05 (Total lung capacity was similar in all groups and was not significant)
SecondaryExtent of Lung CT Scored Emphysema and and Lung Function of FRC/TLC (Functional Residual Capacity(L)/Total Lung Capacity (L) After Tiotropium

Correlation between improved lung function after tiotropium and extent of lung CT scored emphysema with respect to ratio functional residual capacity divided by total lung capacity. Specifically, correlation of tiotropium induced bronchodilation and extent of lung ct scored emphysema

Time frame:
baseline to trough tiotropium
Reported as:
Mean · percentage of lung tissue
Extent of Lung CT Scored Emphysema and and Lung Function of FRC/TLC (Functional Residual Capacity(L)/Total Lung Capacity (L) After Tiotropium
percentage of lung tissueLung CT Scored Emphysema and FRC/TLC
Extent of Lung CT Scored Emphysema and and Lung Function of FRC/TLC (Functional Residual Capacity(L)/Total Lung Capacity (L) After Tiotropium13.68 ± 18.84
Statistical analysis
  • Lung CT Scored Emphysema and FRC/TLC · Spearman rho · p = 0.36 (A priori threshold for statistical significance: p= 0.05)Spearman rho = -0.26

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tiotropium Bromide 18 µg, Capsule,—0/30 (0%)0/30 (0%)
Placebo—0/30 (0%)0/30 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Entire Study Population
<=18 years0
Between 18 and 65 years12
>=65 years17
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female11
Male18
Region of Enrollment
Region of Enrollment(participants)Entire Study Population
United States23
Canada6
Average participant age +/- SD
Average participant age +/- SD(years)Entire Study Population
Mean70 ± 9
FVC (forced vital capacity)
FVC (forced vital capacity)(liters)Entire Study Population
FVC (L)2.9 ± 1.2
FVC (L) post 180 µg albuterol sulfate MDI3.3 ± 1.2
FVC
FVC(percentage of liters expected)Entire Study Population
FVC percent of liters predicted86 ± 17
FVC post 180 µg albuterol percent of ltrs predict95 ± 16
FEV1(L) (forces expiratory volume) observed
FEV1(L) (forces expiratory volume) observed(liters)Entire Study Population
FEV1(L)1.6 ± 0.6
FEV1(L) post 180 ug albuterol sulfate MDI1.8 ± 0.6
FEV1 (L) percent predicted
FEV1 (L) percent predicted(percentage of liters expected)Entire Study Population
FEV1 percent liters predicted61 ± 69
FEV1 percent liters predicted post albuterol8 ± 6

10 further baseline measures are reported on the registry.

08

Study locations

2 sites
  • Arthur F Gelb MD
    Lakewood, California 90712, United States
  • Noe Zamel MD
    Toronto, Ontario, Canada
09

References and documents

Publications

  • Gelb AF, Gutierrez CA, Weisman IM, Newsom R, Taylor CF, Zamel N. Simplified detection of dynamic hyperinflation. Chest. 2004 Dec;126(6):1855-60. doi: 10.1378/chest.126.6.1855. PubMed 15596684 ↗
  • Gelb AF, Taylor CF, McClean PA, Shinar CM, Rodrigues MT, Gutierrez CA, Chapman KR, Zamel N. Tiotropium and simplified detection of dynamic hyperinflation. Chest. 2007 Mar;131(3):690-695. doi: 10.1378/chest.06-1662. PubMed 17356081 ↗
  • Gelb AF, Fraser C, Zamel N. Lack of protective effect of tiotropium vs induced dynamic hyperinflation in moderate COPD. Respir Med. 2011 May;105(5):755-60. doi: 10.1016/j.rmed.2010.11.020. Epub 2010 Dec 14. PubMed 21159499 ↗

Individual participant data

Plan to share: No — Please see published data

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006, a primary completion of Feb 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2007
First posted
Dec 7, 2007
Start
Oct 2006
Primary completionActual
Feb 2009
CompletionActual
Mar 2009
Results first posted
Oct 5, 2012
Last update
Aug 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00569270
Lead sponsor
Gelb, Arthur F., M.D.
Responsible party
Sponsor
First posted
Dec 7, 2007
Start date
Oct 2006
Primary completion
Feb 2009
Completion
Mar 2009
Results posted
Oct 5, 2012
Last update
Aug 20, 2019

Study contacts

Arthur F Gelb, MD
principal investigator · Arthur F Gelb Medical Corporation
Noe Zamel, MD
principal investigator · Mt. Sinai Hosp. Toronto, Univ Toronto Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion